Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

October 30, 2024

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 62 min

Earnings Call Speaker Segments

Cecilia Furlong

executive
#1

Thanks, Operator, and I appreciate everyone being here today as we go over Penumbra's results for Q3 2024. You can find the press release along with the financial tables — including the reconciliation from GAAP to non-GAAP — on the Investors tab of our website, www.penumbrainc.com. Over the course of this call, we'll be making forward-looking statements under the safe harbor protections of the Private Securities Litigation Reform Act of 1995, covering things like our financial performance, commercialization efforts, clinical trials, regulatory status, quality, compliance, and business trends. Actual results may end up differing materially from what those statements state or imply, because of certain risks and uncertainties — among them those we reference in our 10-K for the year ended December 31st, 2023, filed with the SEC. So we'd caution you not to put undue reliance on these forward-looking statements, and we'd encourage you to look at our periodic filings with the SEC, including that 10-K I just mentioned, for a fuller discussion of these factors and other risks that could affect our future results or the market price of our stock. Penumbra takes no obligation to update or revise these forward-looking statements, whether because of new information, future events, developments, or anything else. On today's call, revenue and gross margin figures are on a GAAP basis, whereas operating expenses, operating income, and adjusted EBITDA are on a non-GAAP basis. You'll find the corresponding GAAP measures and the reconciliation between GAAP and non-GAAP financial measures in the press release we posted. Non-GAAP operating expenses and operating income leave out expenses tied to winding down our Immersive Healthcare business in the third quarter of 2024 totaling $5 million, a one-time expense of $18.2 million from the acquisition of IPR&D in the third quarter of 2023, and amortization of acquired intangible assets of $2.4 million in the third quarter of 2023. Adjusted EBITDA for the third quarter of 2024 came to $56.7 million, which excludes the wind down expenses, stock compensation expense, depreciation and amortization, provision for income taxes, and interest income expenses. Adam Elsesser, Penumbra's Chairman and CEO, will give a business update. Maggie Yuen, our Chief Financial Officer, will then talk through our financial results for the third quarter of 2024, and Jason Mills, our Executive Vice President of Strategy, will go over our 2024 guidance. With that, I'll hand the call over to Adam Elsesser.

Adam Elsesser

executive
#2

Thanks, Cecilia. Hello, everyone, and good afternoon. I appreciate you being on the call for Penumbra's Q3 2024 earnings discussion. During the third quarter, our total revenue came to $301 million, which was up 11.1% versus the same period last year as reported, and 10.9% in constant currency terms. Once again, our U.S. thrombectomy segment turned in a robust showing in Q3, fueled by ongoing uptake and deeper market penetration of the CABT products we currently offer—Lightning Flash 2.0 and Lightning Bolt 7. U.S. thrombectomy climbed 21.2% compared with a year earlier, reaching $162.1 million, while our U.S. VTE franchise posted 32% revenue growth year-over-year and 13% quarter-over-quarter. The rest of our U.S. thrombectomy franchise kept delivering very solid results, matching what we had anticipated. During the quarter, the FDA granted clearance for 2 additional CABT products—Lightning Bolt 6X and Lightning Bolt 12—which further strengthen and expand an ever more comprehensive CABT lineup. I'll share more specifics about these products afterward in my prepared comments. On top of that, we obtained CE Mark for Lightning Flash 2.0 and Lightning Bolt 7 in the middle of September, and we're in the early stages of bringing this transformative technology into European markets. Our profitability improvement trend carried on in Q3, as gross margins rose to 66.5%, an increase of 90 basis points from the prior-year period, and non-GAAP operating income reached $40.3 million, equal to 13.4% of revenue in Q3, up 110 basis points from a year ago. Thanks to a favorable product mix shift and operating efficiencies, we still foresee a gross margin profile above 70% over the coming 18 to 24 months, and we anticipate non-GAAP operating margin expansion will exceed gross margin expansion for the foreseeable future. Furthermore, with strong revenue growth, growing gross margins, and disciplined operating spend this quarter, we produced $51.3 million in operating cash before factoring in the effect of our $100 million stock buyback. We're well positioned to keep boosting our profitability and operating cash flow going forward. In our U.S. peripheral business, the highlight of the quarter was Lightning Flash 2.0. Flash 2.0 reliably clears blood clots in VTE patients much more quickly than any earlier products. Because the procedure is now so fast with Flash 2.0, there's no meaningful blood loss; this Flash 2.0 technology stacks up very favorably against other companies' older technology, which requires far more time to remove blood clots and causes enough blood loss that physicians feel compelled to give blood back to patients. Consequently, Flash 2.0's performance keeps drawing physician interest, and our Q3 results show strong adoption of our newest Flash technology in its first full quarter on the market, with September being our highest month ever for VTE procedure volumes as we keep capturing VTE market share. Flash 2.0's speed was crystal clear in a PE case this quarter, in which a firefighter who was 39 weeks pregnant was treated for a very serious PE using a Flash 2.0. The patient and her baby were saved because of how quickly the procedure was performed. It was a privilege for me to watch a video showing her and her baby, at the time of her discharge from the hospital, being welcomed by a row of firefighters. Also, we obtained FDA clearance for Lightning Bolt 12, which broadens our lineup of newest-generation CABT products built to tackle VTE. Lightning Bolt 12 merges our patented modulated aspiration technology, which Lightning Bolt 7's robust clinical results have validated, with a catheter size intended to reach smaller portions of the venous anatomy. The first cases have performed very well, and this technology widens the pool of VTE patients whom we are able to treat using our CABT technology. Although we anticipate only modest initial contributions during the fourth quarter, as we look toward 2025 and beyond, we believe CABT's proven value proposition and our ever more comprehensive VTE-focused CABT catheter portfolio will help speed up conversion away from other mechanical thrombectomy products, lytics, and medical management. Our U.S. arterial business, headed by Lightning Bolt 7, kept performing strongly in the third quarter. FDA clearance of Lightning Bolt 6X in September extends still further the reach of our advanced CAB technology into smaller arteries, such as below-the-knee arterial occlusions, where our legacy catheters are presently used to treat a share of the patient population. Bringing in Lightning Bolt 6X will deliver CABT's benefits, better procedure efficiency, and a decrease in procedure times to these patients. As with Lightning Bolt 12, we anticipate modest contributions from 6X in the fourth quarter while we begin commercialization. Even so, we perceive a meaningful opportunity for our arterial-focused CABT portfolio, which today includes Lightning Bolt 7 and Lightning Bolt 6X, to speed up physician conversion away from open surgery or the use of lytics toward a computer-assisted endovascular-first approach for treating arterial clot. Notwithstanding substantial progress so far, we are still in the early stages of helping the more than 800,000 patients each year in the U.S. who suffer from VTE and arterial clot with our proprietary CABT technology. Shifting to the neurovascular business, our team once again delivered a solid double-digit performance in stroke thrombectomy. With interest fading in the super large bore 088 catheters as aspiration catheters, the majority of companies holding those products have moved to positioning them as guide catheters; this puts us in a very strong position with our market-leading aspiration portfolio, headed by RED 72 with our proprietary Sendit technology and RED 43, as we get ready to bring Thunderbolt and the benefits of our CABT technology into the neurovascular field. As we stated previously, our Thunder trial has recently finished enrollment, with follow-up expected to wrap up by the end of the year; we will give additional future updates as appropriate, but obviously, we are thrilled about the prospect of bringing CABT and its demonstrated clinical benefits and procedural advantages into the neurovascular field to further solidify and enhance our market-leading position in stroke thrombectomy. Now moving on to what we’re doing outside the U.S. In September, Lightning Flash 2.0 and Lightning Bolt 7 got CE Mark, which widens where our newest CABT technology can be used around the world. There’s a lot of enthusiasm among physicians in European markets for this technology, and although we’ve started making some initial sales, we anticipate that revenue will build up gradually because of the reimbursement situation right now in that region. Still, looking ahead, we believe there’s a chance for CABT in markets internationally, and that’s supported by the reimbursement and clinical evidence work we’re doing at present, along with solid commercial execution. When we think about 2025 and after, we see a major opportunity for CABT to change how blood clots are handled and treated on a global scale. In the short term, our attention is on carrying out a four-part strategy we’ve already described. First, ongoing innovation to keep improving CABT’s full value proposition and to grow the number of patients with clot burden who can be treated with CABT therapy in a way that’s safe, effective, quick, and easy. Second, generating clinical and health economic data through randomized clinical trials, real-world studies, and our market access efforts to raise awareness of not just the outcomes and benefits of CABT, but also the economic advantage for hospital systems. Third, putting money into our commercial and market access teams so we can fully unlock CABT’s potential and support growth that’s sustainable and strong in how many patients can benefit each year from a computer-assisted interventional approach. And fourth, carrying out our strategy with a disciplined emphasis on improving operating efficiencies and a profitability profile that keeps getting better. I’ll hand the call to Maggie now so she can review our financial results for the third quarter.

Maggie Yuen

executive
#3

Thanks, Adam, and good afternoon, everyone. During this call, I'll take you through how we performed financially in Q3 2024. The revenue and gross margin numbers we're covering are on a GAAP basis, while operating expenses and operating income are non-GAAP. The matching GAAP figures, plus our reconciliation between GAAP and non-GAAP financial measures, are available in the press release we issued. In the third quarter, which closed on September 30, 2024, total revenues reached $301 million, an 11.1% increase as reported and 10.9% higher in constant currency compared with the third quarter of 2023. In terms of our sales mix by geography for Q3 2024, the U.S. accounted for 75.2%, while international markets contributed 24.8%. Growth in our U.S. region was 16.2%, powered by a 21.2% rise in our thrombectomy franchise. Our international regions declined 1.9% as reported and 2.5% in constant currency, primarily due to China revenue dropping by $13.6 million, a decrease that was offset by a $12.2 million gain across all other international regions. The 0.5% sequential increase in our total revenues was driven mainly by an $8.3 million rise in our U.S. thrombectomy revenue and relatively flat revenue in Europe, partly offset by a $9.4 million decrease in China revenue. Now looking at revenue by products, our global thrombectomy business generated $204.1 million in the third quarter of 2024, reflecting growth of 14% as reported and 13.8% in constant currency versus the same period last year. Our 21.2% growth in the U.S. is primarily due to continued adoption of CABT. Our international business declined 7.1%, largely as a result of lower China revenue, which was offset by growth in all other international regions relative to the same period last year. Revenue from our embolization and access business was $96.9 million in the third quarter of 2024, up 5.5% as reported and up 5.2% in constant currency, which is in line with what we anticipated and mainly reflects an increase in the U.S. Gross margin for the third quarter of 2024 was 66.5%, compared with 65.6% for the third quarter of 2023; we delivered 90 basis points of improvement, driven by a favorable thrombectomy product mix across all regions along with strong productivity gains. Sequentially, we also saw a 100 basis point improvement in gross margin, excluding the one-time $33 million Immersive Healthcare inventory write-off taken in the second quarter of 2024, which reflects a higher thrombectomy product mix and a favorable distributor mix. Our manufacturing team will focus on scaling up volume while continuing to drive productivity and efficiency for our new product launches in the fourth quarter. Research and development expenses for the third quarter of 2024 were $25.2 million compared to $21 million for the third quarter of 2023. Let me now move to our non-GAAP operating expenses, non-GAAP operating income and margin, and Adjusted EBITDA. Total operating expense for the quarter was $160 million, or 53.1% of revenue, versus $144.5 million, or 53.3% of revenue in the same quarter last year. Turning to research and development, our Q3 2024 spend came to $22.6 million, versus $21 million in Q3 2023. Wait, I should correct that — R&D for Q3 2024 was actually $25.2 million compared to $21 million for Q3 2023. On SG&A, for the third quarter of 2024 we recorded $137.4 million, which works out to 45.6% of revenue, against $123.5 million, also 45.6% of revenue, in the third quarter of 2023. Operating income for Q3 2024 landed at $40.3 million, or 13.4% of revenue, compared with $33.2 million, or 12.3% of revenue, in the same period a year earlier. Late in the quarter — during the back half — we wound down our Immersive Healthcare business, and that generated roughly $6 million in GAAP operating expense savings. Looking ahead, we expect to deliver approximately $40 million in annual GAAP operating expense savings. With a full quarter of Immersive Healthcare savings behind us, we anticipate that sequential margin expansion will continue into Q4 2024. Adjusted EBITDA came in at $56.7 million, equal to 18.8% of total revenue, versus $51.5 million, or 19%, in last year's third quarter. Now on to cash flow and the balance sheet: we ended Q3 with $291 million in cash, cash equivalents, and marketable securities, and no debt — a sequential decline of $48.7 million stemming from the $100 million stock repurchase executed during Q3 2024. Without that stock repurchase, our operating cash rose by $51.3 million, driven by operational profitability and better working capital management. We still expect positive operating cash flow trends through the remainder of 2024 and beyond, and at this point I'd like to hand the call to Jason to walk through our guidance.

Jason Mills

executive
#4

Thanks, Maggie, and hello everybody this afternoon. Our guidance range for total revenue in 2024 stays as it was — $1,180 million to $1,200 million. There's a single quarter left in the year, and we feel good about expectations sitting in the middle of that range, the same place they stood when we began this call. On top of that, for U.S. thrombectomy growth in 2024, we're lifting the bottom of our range to 24%-25%, up from 23%-25% before. Further along the income statement, gross margin for the fourth quarter should match what we saw in the third quarter, and we look for non-GAAP operating margin to grow on a sequential basis. If you set aside the Immersive Healthcare impairments, those figures would line up with our full year guidance: 100 to 150 basis points of gross margin improvement and 100 to 200 basis points of operating margin improvement. Operator, please go ahead and open the line for questions.

Richard Newitter

analyst
#5

Hello, and thank you for allowing me to ask. To kick things off regarding U.S. thrombectomy, that figure came in at a robust 22%. From what I recall, you mentioned U.S. venous, or VTE, stood at 32%. Could you walk us through the U.S. neuro-thrombectomy component? Based on my own math — though it could be off — it seems to point toward a notable slowdown during the third quarter. Is my understanding correct? And what's the right way to view that trend, both now and moving ahead?

Adam Elsesser

executive
#6

Yes, I appreciate that question, thank you. Our stroke segment delivered quite a strong performance, with growth in the high double digits. So I wouldn't characterize that as any kind of deceleration. If you recall what makes up U.S. thrombectomy, there's neuro, arterial, peripheral arterial, coronary, plus VTE — and clearly coronary, which has been on the market with our legacy product for a great many years, sits in the single digits; that, I believe, explains the difference, while neuro performed very well in this quarter.

Richard Newitter

analyst
#7

All right, my calculation was off — apologies for that. Nice work on that U.S. neuro growth rate; it's really strong. Maybe just regarding the overseas side and China, how does this shape what you expect for a rebound in those markets? And looking ahead to 2025, the international business still seems fairly hard to predict; so how much visibility do you have, and how should we think about the contribution from new products in some of the places where you're only now starting to launch, in terms of offsetting that? Thanks.

Adam Elsesser

executive
#8

Yeah, good question, I'd say. Look, during the prior quarter we discussed China and what's going on for us there, especially the shift from our licensing revenue approach to the distribution approach that's included in our deal. We devoted a lot of time in that quarter to explaining it. So honestly nothing has shifted. It's simply appearing now. So we've already factored that in. There's nothing new to report on that front. Of course, if China bounces back, that would be a benefit down the road, whether that comes in the latter half of 2025, in 2026, or later still. There are definitely far fewer headwinds internationally in 2025 compared with 2024. And there are some genuine bright spots, as we highlighted during this call, with the Flash 2.0 launch, plus Lightning Bolt 7. Clearly, there's plenty of enthusiasm. There are many discussions happening between physicians in the States who use it and their counterparts in European markets, and I believe as we bring it to market, that portion of the business is going to perform extremely well, so there isn't much fresh news regarding our international markets. Things are unfolding the way we've described them for some time.

Richard Newitter

analyst
#9

Okay, thank you very much.

Adam Elsesser

executive
#10

Thank you.

Robbie Marcus

analyst
#11

Oh, excellent. Thanks for fielding the questions, and congratulations on a solid quarter. I've got two. To start, I'd like to ask about the margin expansion. Once again it arrived in strong fashion. We noticed some favorable movement there, particularly when it comes to EPS. What's the right way for us to frame your capacity to keep pushing this margin expansion forward? Is this a case where 100 to 200 basis points is a reasonable band to apply as long as thrombectomy keeps expanding at those elevated levels, or is there a one-time element in 2024?

Adam Elsesser

executive
#12

Yeah, if gross margin is what you mean, that's a longer-term effort we've been describing for some time now, which is that it combines efficiencies along with the product mix shift as a larger portion of that business comes from our CABT platform. So that will keep going. If operating margin is what you mean, once more, we believe that too will grow faster than the gross margin. And I'd say this is a quarter that resembles certain prior quarters in demonstrating that we've got a genuinely profitable business here. And we're capable of doing both. Clearly we can put money into this, and we've again spelled out pretty clearly the four-prong strategy through which we can put money into innovation. We'll put money into the clinical data across a range of approaches, and also into expanding our commercial and market access teams. Every one of those investments is aimed at growth, while at the same time doing so within a very, very profitable business. So I believe we were quite clear about that in the prepared remarks; that hasn't shifted from before. It's simply more evident than ever at this point, and I think this quarter highlights that quite sharply.

Robbie Marcus

analyst
#13

My question was actually about operating margin, so you ended up addressing both anyway. That works for me. And then.

Adam Elsesser

executive
#14

I just wanted to make sure nothing was left out for you.

Robbie Marcus

analyst
#15

Thanks for that. I just got back from TCT today, and yesterday we saw the PEERLESS data that came from your competitor. So I suppose my question is this: do you believe the clinical community will treat that as something unique to your competitor, or will they apply it to thrombectomy more broadly and have it affect your business too? Thanks.

Adam Elsesser

executive
#16

Yeah, look, I want to be careful not to say anything out of line here, but considering how restrained the response has been that we've observed and heard from the majority of physicians, we definitely are hoping it isn't seen as applying to every product. Clearly, a few of the specifics in there weren't a shock when you consider the procedure itself, how long the procedure took with their older devices, and frankly the bleeding rates, which aren't the case anymore with Flash 2.0. So I'd say CABT and 2.0 are drawing a great deal of attention; and based on everyone we've spoken with there in person, along with those who are reading that, I think all of us are looking beyond that specific kind of study and toward the more significant comparison, which is the one against anticoagulation, the way we're conducting it in our STORM study. And I'd say that's where the genuine momentum in the field lies, and that's where the interest is. So I suppose, taking those issues into account, we weren't taken aback by the somewhat restrained response, but I don't view it as a negative for us in any way.

Robbie Marcus

analyst
#17

Thanks, I appreciate that.

Larry Biegelsen

analyst
#18

Hello, this is Larry, and I'm on the line for Larry. I appreciate you taking my question. To begin with the Thunder trial, nice work on getting all the patients enrolled. On clinicaltrials.gov, we noticed that the sample size — the number of patients — is different. It's somewhat smaller than the number you had at the start; also the endpoint is different. A safety endpoint is different too. Could you speak to those points, and did the FDA sign off on them? I have one more question after that.

Adam Elsesser

executive
#19

The FDA did sign off on those changes. That's correct.

Larry Biegelsen

analyst
#20

Okay. For both of those changes?

Adam Elsesser

executive
#21

Yes.

Robbie Marcus

analyst
#22

All right, that's great. Thanks. And Adam, you've brought this up a handful of times previously, and once more during today's call — that headwinds are reduced in 2025 compared with 2024. Could you explain which of those headwinds are set to disappear in 2025 as opposed to 2024, and what extra tailwinds might emerge for us in 2025? Thank you.

Adam Elsesser

executive
#23

Yeah, fair question. A few of the items we discussed during this year — early on, we spoke about recalibrating, in a sense, and selling certain of our embolization products plus our access products across particular international markets where reimbursement had dropped so far that the business was no longer viable; clearly that's one major problem that won't be present in 2025. We've touched on China across the past few calls and on recalibrating there as we shift into the next phase. And then there's the delay, so to speak, in bringing CABT to Europe. So those are roughly the major subjects we were facing abroad. And largely, they vanish in 2025. As for what looks favorable, clearly we've also discussed that new product launches are on the way. We have this ongoing share gain with products already on the market, such as what we just witnessed — a rather meaningful share shift once again in yet another quarter with Flash 2.0; so fairly steady momentum there. I think, adding all of that together, we're excited about 2025 too.

Joanne Wuensch

analyst
#24

Thanks so much. There are really a couple of fast questions I want to put forward first. Could you take us through the path you'll follow to reach that 80% gross margin target during the coming 18 months? What portion of it comes from real, or the newly named label for that, or from other things? My next question concerns Thunderbolt. Congrats on finishing the clinical trial and the filing, but I'd like to know about the path toward commercialization and how you expect adoption to go. Thanks.

Adam Elsesser

executive
#25

Yes, those are good questions. Perhaps I heard you incorrectly. My understanding is that you asked about gross margins, and I believe you mentioned taking them to 88% rather than the figure we'd put forward, which was 70%. So I want to confirm whether I got that right. Maybe I didn't, but we believe gross margins can rise past 70%. The major factor is ongoing efficiencies, yet the main thing pushing it is that as we move further and deeper into CABT products, those margins differ, and the mix change is what drives it, so that's the leading force behind reaching the gross margin figure we discussed, or exceeding it. Regarding Thunderbolt, what you raised had to do with commercialization. Rather than getting ahead of ourselves, let's handle the follow-up for that. It's owed. We ought to have it done before this year ends; and then clearly, we'll file it and work through that process. We definitely understand how to bring products to market after 20 years, and we're quite enthusiastic about it. Still, let's hold off until the trial can be formally wrapped up with the follow-up and we can proceed, and at that time we'll provide you with fresher details.

Joanne Wuensch

analyst
#26

Thanks. My apologies if I made your targets too ambitious.

Adam Elsesser

executive
#27

Honestly, that's a solid target to aim for internally. No, I'm only kidding.

Michael Sarcone

analyst
#28

Hi there, good afternoon, and thanks for taking my question. So the first one from me — really impressive growth in U.S. VTE. Could you perhaps walk us through where you believe your share is landing right now across both PE and VTE?

Adam Elsesser

executive
#29

I'd say it's likely too early for that. Maybe we'll handle it at year-end, the way we did a year ago, to do a kind of recalibration. Clearly, each quarter this year, we've been seeing a shift in share going our way. That said, when it comes to attaching precise figures, I'd say it's too soon. We'll look at doing that once more when the year wraps up. The PE side has been quite substantial. We were already doing fairly well in DVT, essentially splitting that business 50/50. Yet we've witnessed an enormous shift when it comes to PE. Much of that truly traces back to what I mentioned. The product, Flash 2.0, is incredibly fast, the length of the procedure is dramatically different, and there's no meaningful blood loss whatsoever. So as a result, you don't feel that same unease, that same concern about losing so much blood that you'd need to return it via other products and so forth to make that happen; and that's simply, by definition, if you're able to remove all the clot far more quickly and have no problem requiring you to put anything back, that's a better outcome for the patient. It can get patients stabilized far more quickly; and honestly, I believe it signals something really, really positive for what's ahead; and once again, it speaks to the necessity of continually innovating in these areas. Things evolve, products keep improving. And I'd hope every one of us is enthusiastic about that and celebrates it; that's essentially the whole purpose of innovation, which we've clearly been recognized for over the last 20 years.

Michael Sarcone

analyst
#30

Understood. Adam, that's useful. Thanks. As a follow-up, Bolt 6X and Bolt 12 have just received FDA clearance. For each account, you must complete VAC processes before those can be sold. Could you describe that process, and perhaps also address pricing and what effect it has on P&L economics?

Adam Elsesser

executive
#31

Yes, sure, a few points. Starting with price. Clearly, CAVT products carry a somewhat different price point compared with non-CAVT offerings. So when set against legacy products — which amount to nothing more than the catheter plus the original pump — a difference will clearly exist. Regarding the process, right, I don't know of any universal exemption that lets you skip it for new products; these clearly are new products. That process will be undertaken by us; and once more, since we've brought multiple products to market annually across a great many years, I believe we understand how it's done and we'll continue. However, the VAC process is something they must undergo.

Michael Sarcone

analyst
#32

All right, thanks, Adam.

Adam Elsesser

executive
#33

Yeah, thank you.

Samantha Kurtz

analyst
#34

Hello, Samantha here, filling in for Matt. We appreciate you answering our question. I'd like to dig deeper into the 6X as well as the new Bolt 12 devices, and I suppose beginning with the 6X, could you elaborate a bit further on what separates the below-the-knee catheter from the upper one? Is the only distinction the catheter's dimensions, and then perhaps discuss a few of the competitive dynamics currently at play in the arterial market as well.

Adam Elsesser

executive
#35

Sure, regarding catheter dimensions, it is clearly somewhat smaller. The figures, 7 French, 6 French, you'll observe that the more diminutive it is, the more distal it can reach. So not merely below the knee, but into tinier arteries elsewhere in the body too, which I referenced during the prepared remarks. And that is simply the organic progression of CABT as we extend it to additional locations. The X component of the 6X is essentially an instrument comparable to what we refer to as Sendit within the neuro field, where we assist in advancing the catheter and navigating it toward more distal locations; so it truly is about tracking ease and similar factors; yet on the whole, I believe you've captured the product's essence; it simply travels deeper within the vasculature, allowing us to extract that clot. What was your second question again? Once more, my apologies. Was it regarding 12 or?

Samantha Kurtz

analyst
#36

12.

Adam Elsesser

executive
#37

Could you repeat the latter portion of what you asked?

Samantha Kurtz

analyst
#38

Well, just competitive.

Adam Elsesser

executive
#39

Oh, competitive arterial.

Samantha Kurtz

analyst
#40

Oh, arterial competition.

Adam Elsesser

executive
#41

Yes, on the arterial side. My mistake — apologies. Most people, I believe, are aware that competition in this area is limited. Plenty of businesses out there have assorted gadgets and such. This same dynamic, I think, has been visible in brain stroke for a number of years; that battle unfolded over a long stretch in stroke. Aspiration gets results. When it comes to aspiration, the underlying science is quite well established. By now, I believe people in the neuro field grasp that, and it appears to be paying off, and on the vascular side, within the arterial segment, folks are beginning to see this quite plainly, so few companies are directing attention there, and for sure, none of them offer the modulated aspiration that Lightning Bolt 7 and Lightning Bolt 6X give us, and that truly transforms everything. It essentially establishes a fresh category, so to speak, of technology. So honestly, our real battle, the rivalry we face, so to speak, comes from open surgery, anticoagulation, and lytic as well. That's where we direct our efforts, and that's where we've kept our attention. And that is what has driven the ongoing expansion of that business, so to speak, from one quarter to the next.

Samantha Kurtz

analyst
#42

Great. Thanks. And just one more quick item. I realize we've discussed the vendor trial a few times during this call. From another angle, since the follow-up wraps up at the conclusion of the year, when might we anticipate seeing data from that trial?

Adam Elsesser

executive
#43

I won't do that, because a few years ago I clearly made an error by giving out dates for when trials would finish and such, so I won't commit to a particular date. Naturally, once we have that answer in a highly concrete form, we'll inform everybody. Naturally, we're quite eager to share it, but the exact timeline will be updated once we have it, once we have additional information and the trial is complete.

Samantha Kurtz

analyst
#44

Great. Thank you.

Adam Elsesser

executive
#45

Thank you.

Mathew Blackman

analyst
#46

Hey there, everyone. Is my audio coming through fine?

Adam Elsesser

executive
#47

Yes.

Mathew Blackman

analyst
#48

Thanks. I had a few questions about stroke. First off, I'm just wondering, do you think the current rate of growth in U.S. stroke can hold up until Thunderbolt arrives? Then I'll just throw in my follow-up. Medtronic and Philips said last week they're teaming up. I believe the focus is stroke awareness — what effect, if any, do you think that might have on the market down the road? And it may not be the case, but does a device maker joining forces with an imaging company carry any competitive ramifications? I'd just like to hear what you think about that.

Adam Elsesser

executive
#49

Yeah, let me take that one first, and then I'll get to whether our stroke growth can be sustained. Seeing that made me really happy. The more people spread the message that stroke patients ought to be treated, well, this was proven conclusively more than 10 years back across numerous randomized trials. So I believe that's terrific. My sense is there's no impact tied to any particular device. After all, we're all aware that doctors will choose whichever product performs best and removes the clot most quickly; and the only thing we ought to do is cheer on everyone — imaging businesses, device businesses, hospital systems in their own communities — for raising all sorts of awareness. We've taken part in many efforts to spread awareness of this, partnering with several of the major societies, Get Ahead of Stroke, as you're aware, through the years, and I cheer it on, and I'm happy to see it, and I believe it benefits a great many patients, so count me fully supportive. When it comes to how our stroke business is growing, I feel we're positioned very, very well. Like I said on the call, plenty of companies offer these super bore catheters. That enthusiasm is plainly fading now that people get it and see that perhaps they work better as guide catheters, which is quite distinct from an aspiration catheter. I believe that has truly set the stage for what I expect will be a solid stretch for our stroke business, plus plenty of buzz as we get closer to launching Thunderbolt in the neuro space too.

Mathew Blackman

analyst
#50

All right, appreciate it. Thanks.

Adam Elsesser

executive
#51

Thank you.

Mike Kratky

analyst
#52

Hello, everybody. We appreciate you fielding our questions. Regarding the arterial segment, could you share additional details about how much your U.S. arterial thrombectomy business expanded in 3Q, and whether the very robust trajectory observed so far in that area persisted? Then, as a second question, did anything particular stand out during 3Q within that segment that might explain any variance from the recent growth pattern, assuming such a variance existed?

Adam Elsesser

executive
#53

No. Our arterial operation expanded within the high teens against rather difficult year-over-year comparisons created by the Lightning Bolt 7 introduction; therefore we felt extremely positive regarding that arterial segment's expansion. The product performs, folks. Honestly, it truly is that straightforward. Lightning Bolt 7 genuinely performs. Lightning Bolt 6X genuinely performs. Plus it removes the clot rapidly and without difficulty. Few problems exist in that area. Thus I believe we are witnessing that trend persist. Once more, we simply are putting in the effort while rolling out 2.0, keeping up introductions of the completely new offerings, and maintaining penetration efforts with 7. Our field personnel are kept busy discussing several of the most groundbreaking products this industry has ever witnessed. Yet that operation remains extremely robust at present.

Mike Kratky

analyst
#54

Got it. Appreciate the detail. So perhaps just a single fast question. When it comes to the BTK area, would you frame that more as a story about expanding the market, or do you figure it's likely to be more about greater utilization?

Adam Elsesser

executive
#55

Honestly, it comes down purely to how big the catheter is. If you look back to the period before CABT existed, we weren't really categorizing them as below the knee or not, since whatever catheter size could reach the clot was the one you'd pick. That shifted somewhat once CABT was available only on a catheter size that truly cannot reach below the knee — that being the Bolt 7. Now that it's on a catheter able to travel further down past the knee, we're delivering that CABT there. Our aim is to extend the CAB technology into every region of the body containing blood clot where CABT might help. And we aren't completely finished; from that point we'll keep innovating onward. So that plan is already well in motion. Once more, within the four-pronged strategy I described quite explicitly, innovation ranks first. For Penumbra, innovation has always ranked first, which is why we ensured that point came through unmistakably. We'll keep extending CABT technology into every region of the body that stands to gain from clearing the clot far quicker and far more safely.

Mike Kratky

analyst
#56

Awesome. Thanks, Adam.

Adam Elsesser

executive
#57

Thank you.

Pito Chickering

analyst
#58

Hi everyone, and thanks for letting me ask. I've got a quick question about guidance. You're lifting your U.S. thrombectomy outlook to slightly above the street, yet keeping total revenue guidance the same. Has anything else shifted in the other parts of your guidance?

Adam Elsesser

executive
#59

No, I don't believe so.

Jason Mills

executive
#60

During Q4, I did provide that outlook, and what we indicated was that we feel at ease with the midpoint. Clearly, that would mirror at minimum the middle point of the fresh 24%-25% range. When you build out your model for thrombectomy outside the US, we have previously discussed the pressures we are encountering abroad, particularly in China. That is what this reflects. However, if you take the midpoint of the guidance, then obviously Q4 comes out to roughly 20% growth for US thrombectomy — that is what the midpoint of guidance implies. As for the remaining parts of the business, I believe the street is forecasting them more or less suitably.

Pito Chickering

analyst
#61

All right. Great. Margins, one more question. I get that gross margin is widening because a favorable mix provides those tailwinds. Yet when I zero in on SG&A leverage, what's the right way to think about balancing revenue growth against the investments made to fuel it? What amount of leverage are you able to generate across the coming couple of years? It looks like there's room for considerable SG&A leverage over the next three to five years. Should we expect something like 50-plus basis points of margin expansion each year from SG&A across the next couple of years?

Adam Elsesser

executive
#62

Yeah. Rather than hand you a particular figure, I believe we've made it fairly clear that we're genuinely able to accomplish both at once. We're able to put substantial money into what counts; and once more, that truly traces back to the four-pronged strategy, meaning ongoing innovation, the data that will matter for keeping the thrombectomy business growing, plus the commercial team and the market access team that will propel genuine market growth down the road. And accomplish all of that while still operating a business that's quite substantially profitable; and I think this quarter demonstrates that; and we will keep doing so moving forward.

Pito Chickering

analyst
#63

Great. Thanks so much.

Adam Elsesser

executive
#64

Thank you.

Analyst

analyst
#65

Hi everybody; this is McCauley-Ann calling in from Margaret this evening. We appreciate you fielding our question. There's been plenty of talk about revising the guidelines, clearly, in the wake of the data presented at TCT this week, and I realize it was specific to one product, yet when we consider the more distant future of adoption for thrombectomy and CABT especially, I suppose, what's your thinking on recommendations that alter guidelines, and in the end, how does that connect to the market access efforts you've kept pursuing behind the scenes?

Jason Mills

executive
#66

Yeah. My view is that it truly hinges on which vascular bed you mean. Your focus is PE. Clearly, PE comes up constantly for us. I'll get to that in a moment. Yet DVT exists too, which, as I believe you're aware, involves a bigger patient count, plus arterial, which likewise involves more patients than PE does. So at present the guideline concerns are sharpest for PE. And honestly, if you simply consider the figures, 85% of the patients within the PE population continue receiving anticoagulation. Roughly 10% receive mechanical thrombectomy on the other side. I believe 5%, assuming my figures tally, receive catheter-directed lysis; thus a guideline revision concerning the 2, 3, 4, 5% isn't truly pertinent; and it would be somewhat irrelevant for guidelines to shift regarding one particular product, especially considering how most physicians responded to those data. My sense is the field truly awaits trials reporting anticoagulation endpoints. After that, guidelines will probably shift. I doubt it would target a single product, even when that product is ours. That genuinely halts innovation, and nobody wishes to halt innovation. What you should do is demonstrate the concept, proceed, keep innovating, and grow better and better; and my mind goes back over 10 years, when the stroke trials were published, and there was no genuine appetite to halt innovation. So it was interventional means. What is employed now compared with what was employed a decade ago in stroke differs enormously. Still, the principle remains. So that's my perspective on where this field heads from here.

Analyst

analyst
#67

That's excellent. As a quick follow-up, I recognize the bigger factor here is the CABT platform on its own; however, we've been hearing a fair amount of encouraging feedback about this week's Select Plus launch. So, has it managed to generate any additional growth comparable to what happened when Sendit was first introduced, as a sort of benchmark?

Adam Elsesser

executive
#68

Yeah, well, thanks for bringing that up. Normally we don't discuss inner catheters such as Select Plus. Their purpose is basically to help cases go more quickly and smoothly. Select Plus has gotten a really strong positive response; it has certainly drawn plenty of attention and helped cases move even quicker when it comes to accessing the case. So it truly falls under the Flash 2.0 umbrella. When you're simply completing Flash 2.0 from beginning to end far more rapidly, delivering it there sooner, extracting a clot now incredibly quickly, all of that together creates the sense that this was truly an outstanding case. And my belief is that will keep being what people are drawn to for a good while.

Analyst

analyst
#69

Excellent, thanks for letting me ask.

Adam Elsesser

executive
#70

Sure, I appreciate it.

Chris Pasquale

analyst
#71

Thank you. Adam, I'd like to build on what was asked regarding Bolt 12 and 6X. Do you have a rough idea of what share of venous and arterial clots happen in vessels too small for Flash or Bolt 7 to reach? Also, are you currently treating those cases with products that aren't CABT, or do those patients require a different treatment or surgery?

Adam Elsesser

executive
#72

Yes, that's a fair question. I lack solid figures, so I'd rather not simply toss out additional estimates regarding the percentages, whether we're talking about 12, the venous space, and part of it comes down to preference too. In certain cases, people prefer a smaller catheter, and so forth. But the response to, I believe, the more important question is: are we handling those cases at present? Usually, when mechanical methods are being used, we are involved in those cases; they're simply relying on the non-CABT as long as they require the smaller-sized product. That therefore gives us a chance to advance and deliver the CABT products into those vascular beds. And typically, those physicians have already seen them through our larger systems, on both the arterial and venous side. So all of them are eager to obtain the benefit of CABT within those smaller vascular beds. So I believe it's a fairly clear way of seeing it; and I think it will simply, once again, it will deliver the benefit to those patients in the smaller vascular beds through CABT.

Chris Pasquale

analyst
#73

That's useful, thank you. Next, you said that limits around reimbursement in Europe might cause Flash and bolt to be taken up at a slower, more careful pace. Are there ways you could pursue step-by-step reimbursement gains, perhaps via further clinical trials within individual countries or similar efforts?

Adam Elsesser

executive
#74

Yes. Let me first address the term you chose. Reimbursement isn't truly a worry for us. What we want is to secure suitable reimbursement for these products. Clearly, when a computer gets added to each chip, the cost rises; this isn't comparable to a catheter plus a syringe. The product is of a very different kind, which inherently means extra effort is needed to obtain that reimbursement and to demonstrate it; so yes, chances will exist to accomplish that through various approaches, data included, without question; and I believe I brought that up earlier. Looking back at the four-pronged strategy, alongside that innovation sits the creation of data, which will keep fueling this growth, so it belongs in that category.

Chris Pasquale

analyst
#75

Great. Thank you.

Adam Elsesser

executive
#76

Thank you.

Mike Matson

analyst
#77

Yeah, thanks. I've got a couple of questions about Thunderbolt. First, on the Thunder trial — do you expect we'll get a look at the data at some point, perhaps during the first half of next year, ahead of your FDA submission? Then, on Thunderbolt pricing, I realize you won't share the actual figure, but will it carry a premium roughly comparable to what we've seen on the venous side?

Adam Elsesser

executive
#78

Yeah, those are good questions. We haven't even started to think through exactly when the data would be published and presented. Typically, that happens around one of the major neuro meetings. But we haven't. We should finish the trial before sharing anything about when exactly things will happen. I appreciate your understanding on that point. Still, I'm looking forward to pushing through it and wrapping it up. On the pricing side, given how neuro reimbursement works, we're going to set a price that lets hospitals make money on the procedure. That said, it probably will carry a premium. I can't promise it will line up exactly, dollar for dollar, with any specific other CABT product. Because of how reimbursement works in those vascular beds, each one differs somewhat.

Mike Matson

analyst
#79

Okay. Great. Thank you.

Adam Elsesser

executive
#80

Thank you.

Cecilia Furlong

executive
#81

Thanks, operator. From everyone on our management team, we appreciate all of you once more for being with us today and for the interest you've shown in Penumbra. We're glad to bring you up to speed on our call for the fourth quarter.

Operator

operator
#82

This concludes today's call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.